Shire signs monoclonal antibody agreement with arGEN-X
Shire Pharmaceuticals and arGEN-X, a Dutch clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, have agreed a long-term alliance to develop human monoclonal antibodies... SEE AT
http://www.manufacturingchemist.com/news/article_page/Shire_signs_monoclonal_antibody_agreement_with_arGENX/99076/cn48579?dm_i=8EU,2J3KW,9ETTTY,9805Y,1